Laura NuÃ±o-NuÃ±o

List of Publications by Year
in descending order

37	983	623734	454955
papers	citations	14	30
		h-index	g-index

40	40	40	1258
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, 491-496.	0.9	209
2	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. Medicine (United States), 2015, 94, e1144.	1.0	133
3	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. Journal of Clinical Medicine, 2019, 8, 2013.	2.4	118
4	Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. Annals of the Rheumatic Diseases, 2020, 79, 1659-1661.	0.9	67
5	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. Clinical Reviews in Allergy and Immunology, 2017, 52, 71-80.	6.5	60
6	Two populations of circulating PD-1hiCD4 T cells with distinct B cell helping capacity are elevated in early rheumatoid arthritis. Rheumatology, 2019, 58, 1662-1673.	1.9	48
7	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. Autoimmunity Reviews, 2017, 16, 253-257.	5.8	46
8	Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. Rheumatology International, 2017, 37, 1853-1861.	3.0	32
9	Timing of onset affects arthritis presentation pattern in antisyntethase syndrome. Clinical and Experimental Rheumatology, 2018, 36, 44-49.	0.8	30
10	Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry. International Journal of Rheumatic Diseases, 2019, 22, 1393-1401.	1.9	28
11	Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2020, 22, 284.	3.5	28
12	Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. Clinical Rheumatology, 2019, 38, 803-815.	2.2	27
13	A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis. Scientific Reports, 2020, 10, 3355.	3.3	20
14	Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients. Scientific Reports, 2017, 7, 12023.	3.3	17
15	Registro de pacientes con miopatía inflamatoria de la Sociedad Madrileña de Reumatología: análisis descriptivo. Reumatología Clínica, 2017, 13, 331-337.	0.5	14
16	Specific Association of HLA – DRB 1*03 With Anti–Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis. Arthritis and Rheumatology, 2019, 71, 331-339.	5.6	13
17	<i>HLA–B*08</i> Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti–Carbamylated Protein Antibody–Positive/Anti–Cyclic Citrullinated Peptide–Negative Rheumatoid Arthritis. Arthritis and Rheumatology, 2021, 73, 963-969.	5.6	12
18	Influence of MUC5B gene on antisynthetase syndrome. Scientific Reports, 2020, 10, 1415.	3.3	12

#	Article	IF	Citations
19	Improved classification of rheumatoid arthritis with a score including anti-acetylated ornithine antibodies. Scientific Reports, 2020, 10, 19263.	3.3	10
20	Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions. Frontiers in Medicine, 2015, 2, 71.	2.6	8
21	HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine, 2021, 88, 105115.	1.6	8
22	Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain. BMJ Open, 2022, 12, e057850.	1.9	8
23	Circulating CD19+CD24hiCD38hi regulatory B cells as biomarkers of response to methotrexate in early rheumatoid arthritis. Rheumatology, 2020, 59, 3081-3091.	1.9	7
24	The Macrophage Reprogramming Ability of Antifolates Reveals Soluble CD14 as a Potential Biomarker for Methotrexate Response in Rheumatoid Arthritis. Frontiers in Immunology, 2021, 12, 776879.	4.8	7
25	Multicenter Registry on Inflammatory Myositis From the Rheumatology Society in Madrid, Spain: Descriptive Analysis. ReumatologÃa ClÃnica (English Edition), 2017, 13, 331-337.	0.3	6
26	Clinical Characteristics of Juvenile Idiopathic Inflammatory Myopathy and Comparison With Adult Patients. Journal of Clinical Rheumatology, 2022, 28, e195-e202.	0.9	5
27	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. Scientific Reports, 2021, 11, 22574.	3.3	4
28	Correspondence on: â€˜EULAR definition of difficult-to-treat rheumatoid arthritisâ€™. Annals of the Rheumatic Diseases, 2020, , annrheumdis-2020-219500.	0.9	3
29	Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-NaÃ¯ve Early Arthritis Patients. Archivum Immunologiae Et Therapiae Experimentalis, 2022, 70, 12.	2.3	2
30	Lower frequency of anti-citrullinated protein antibodies among early arthritis patients with high body mass index. Clinical and Experimental Rheumatology, 2020, 38, 1155-1160.	0.8	1
31	AB0636â€¦INFLUENCE OF CARDIOVASCULAR RISK FACTORS ON NAILFOLD VIDEOCAPILLAROSCOPY IN THE STUDY OF CONNECTIVE TISSUE DISEASES. , 2019, , .		0
32	FRI0424â€¦DIFFERENCES AND SIMILARITIES ACCORDING TO GENDER IN PATIENTS WITH PSORIATIC ARTHRITIS INITIATING BIOLOGICAL THERAPY. , 2019, , .		0
33	FRI0079â€¦LONG-TERM CLINICAL EFFICACY OF CYCLING VS SWITCHING TO A NON-TNF INHIBITOR IN RA PATIENTS WHO FAILED TO A FIRST TNF INHIBITOR. , 2019, , .		0
34	SAT0063â€¦ASSOCIATION OF SMOKING WITH TRIPLE CONCORDANT SEROPOSITIVITY IN RA PATIENTS, AND WITH RHEUMATOID FACTOR IN THE REMAINING PATIENTS. , 2019, , .		0
35	THU0096â€¦PERSISTENT HIGH DISEASE ACTIVITY IN THE ANTI-CARBAMYLATED PROTEIN ANTIBODY POSITIVE EARLY ARTHRITIS PATIENTS INDEPENDENTLY OF TREATMENT. , 2019, , .		0
36	Myo-Spain: Registro de pacientes con miopatÃa inflamatoria idiopÃ¡tica de EspaÃ±a. MetodologÃa. ReumatologÃa ClÃnica, 2021, , .	0.5	0

#	Article	IF	Citations
37	Myo-Spain: Spanish Registry of patients with idiopathic inflammatory myopathy. Methodology. ReumatologÃa ClÃnica (English Edition), 2021, , .	0.3	0